
AbstractNew combinations of antiangiogenic tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) or...
Posted by : Dr. Guillaume MOUILLET
Journal name : Bulletin du cancer
AbstractNew combinations of antiangiogenic tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) or...
Posted by : Dr. Guillaume MOUILLET
Journal name : Bulletin du cancer
AbstractUntil recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation...
Posted by : Dr. Guillaume MOUILLET
Journal name : Bulletin du cancer
AbstractUntil recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation...
Posted by : Dr. Guillaume MOUILLET
Journal name : Bulletin du cancer
AbstractAim: A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of...
Posted by : Mr. Antoine FALCOZ, Dr. Guillaume MOUILLET
Journal name : Qual Life Res
AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...
Posted by : Dr. Dewi VERNEREY, Dr. Guillaume MOUILLET, Dr. Angélique VIENOT
Journal name : Front Oncol
AbstractIntroduction - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical...
Posted by : Dr. Guillaume MOUILLET, Mr. Antoine FALCOZ, Mme. Joëlle FRITZSCH, , , Dr. Sophie PAGET-BAILLY
Journal name : Quality of Life Research
AbstractBackground: While open-label randomized controlled trials (RCT) are common in oncology, some concerns have...
Posted by : Dr. Guillaume MOUILLET
Journal name : Cancer Med
AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...
Posted by : Dr. Guillaume MOUILLET, Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Bull Cancer
AbstractBackground: Patients with severe renal impairment or undergoing hemodialysis are usually excluded from...
Posted by : Dr. Guillaume MOUILLET
Journal name : Semin Oncol
ABSTRACTBACKGROUND: Two main therapies, pazopanib and sunitinib, are used in the first-line setting for metastatic renal...
Posted by : Dr. Guillaume MOUILLET, Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : Health and Quality of Life Outcomes
ABSTRACTDespite the importance of metastatic clear-cell renal cell carcinoma, studies on its economic burden in daily...
Posted by : , Dr. Guillaume MOUILLET
Journal name : Clinical Genitourinary Cancer
AbstractBackgroundNivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for...
Posted by : , Dr. Guillaume MOUILLET
Journal name : European Journal of Cancer
ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...
Posted by : Dr. Guillaume MOUILLET, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Trials
The measurement of the quality of life in terms of health of people undergoing treatment for cancer is developing. Th is...
Posted by : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Mme. Joëlle FRITZSCH, Dr. Guillaume MOUILLET
Journal name : La revue de l'infirmière
Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...
Posted by : Dr. Guillaume MOUILLET, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JNCI Journal of the National Cancer Institure
BACKGROUND:A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using...
Posted by : Pr. Franck BONNETAIN, Dr. Guillaume MOUILLET, Dr. Sophie PAGET-BAILLY
Journal name : PlosOne